Evaluation of Safety, Immunogenicity, and Preliminary Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Trial

The primary objective of this study is to assess the **safety**, **immune response**, and early **efficacy** of a vaccine for **recurrent vulvovaginal candidiasis** in women. This condition is characterized by frequent episodes of vaginal yeast infections, which can significantly impact quality of life and may lead to complications if not effectively managed. Evaluating the vaccine's safety is crucial to ensure that it does not cause adverse effects, while assessing the immune response will help determine if the vaccine effectively stimulates the body's defense mechanisms against the infection. Early efficacy evaluation will provide initial insights into the vaccine's potential to reduce the frequency or severity of infection episodes.

The clinical trial focuses on **recurrent vulvovaginal candidiasis** and involves a study population exclusively composed of female participants. The age range of the participants is categorized as adults, specifically between 18 to 65 years. The trial does not include male subjects, and no vulnerable populations are selected for this study. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population have not been disclosed, and no principal inclusion criteria are specified. The study aims to gather data pertinent to the specified medical condition within the defined demographic parameters.

The clinical trial is designed to evaluate the **safety**, immune response, and early efficacy of a vaccine for women with **recurrent vulvovaginal candidiasis**. This study is structured as a randomized, controlled trial, with an estimated recruitment start date of November 1, 2023, and an anticipated completion date of December 31, 2025. Participants will be randomly assigned to either the treatment group receiving the vaccine or a control group. The trial will be conducted in a double-blind manner to ensure that neither the participants nor the investigators are aware of the group assignments, thereby minimizing bias.

The trial will include several key study visits. Initially, a screening visit will be conducted to assess eligibility based on predefined inclusion and exclusion criteria. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits to monitor their health status, immune response, and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to evaluate the overall outcomes of the trial.

The expected duration of participant involvement in the study will vary depending on the individual's response to the treatment and adherence to the study protocol. Participants may be withdrawn from the study early if they experience significant adverse effects, fail to comply with the study requirements, or choose to withdraw consent. The trial is designed to ensure the safety and well-being of all participants while providing valuable data on the potential benefits of the vaccine for recurrent vulvovaginal candidiasis.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is scheduled to commence recruitment on November 1, 2023, with an estimated completion date of December 31, 2025. The trial is categorized under phase 7, indicating a specific stage in the clinical research process. Efficacy assessments will be conducted throughout the trial to evaluate the therapeutic impact of the intervention. The parameters for efficacy evaluation, methods for data collection, and analysis schedule are not specified in the provided data. The trial will adhere to a structured timeline to ensure systematic data collection and analysis, although specific timepoints and tools for efficacy assessment are not detailed in the available information.